Related references
Note: Only part of the references are listed.High BRAF variant allele frequencies are associated with distinct pathological features and responsiveness to target therapy in melanoma patients
E. Berrino et al.
ESMO OPEN (2021)
Frequency of mutations in BRAF, NRAS, and KIT in different populations and histological subtypes of melanoma: a systemic review
Luz Dary Gutierrez-Castaneda et al.
MELANOMA RESEARCH (2020)
The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway
David E. Elder et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2020)
Targeting BRAF and MEK inhibitors in melanoma in the metastatic, neoadjuvant and adjuvant setting
Pauline Tetu et al.
CURRENT OPINION IN ONCOLOGY (2020)
BRAF V600E mutational load as a prognosis biomarker in malignant melanoma
Arrate Sevilla et al.
PLOS ONE (2020)
Targeted Therapy in Melanoma and Mechanisms of Resistance
Anna M. Czarnecka et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Frequency and Clinicopathological Profile Associated with BrafMutations in Patients with Advanced Melanoma in Spain
Jose A. Lopez-Martin et al.
TRANSLATIONAL ONCOLOGY (2020)
WNT11-FZD7-DAAM1 signalling supports tumour initiating abilities and melanoma amoeboid invasion
Irene Rodriguez-Hernandez et al.
NATURE COMMUNICATIONS (2020)
Mitotic rate as an important prognostic factor in cutaneous malignant melanoma
A. Pinero-Madrona et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2019)
Satellite and In-Transit Metastatic Disease in Melanoma Skin Cancer: A Retrospective Review of Disease Presentation, Treatment, and Outcomes
Darrin V. Bann et al.
DERMATOLOGIC SURGERY (2019)
Targeting the ERK Signaling Pathway in Melanoma
Paola Savoia et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis
Qiaofen Fu et al.
ONCOIMMUNOLOGY (2019)
Immunohistochemical and Molecular Features of Melanomas Exhibiting Intratumor and Intertumor Histomorphologic Heterogeneity
Haider A. Mejbel et al.
CANCERS (2019)
BRAF Gene Copy Number and Mutant Allele Frequency Correlate with Time to Progression in Metastatic Melanoma Patients Treated with MAPK Inhibitors
Camilla Stagni et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Tumor mitotic rate is an independent predictor of survival for nonmetastatic melanoma
Jessica L. Evans et al.
SURGERY (2018)
Comparison of targeted next generation sequencing (NGS) versus isolated BRAF V600E analysis in patients with metastatic melanoma
Meng-Lei Zhu et al.
VIRCHOWS ARCHIV (2018)
Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 cases
Mario Mandala et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Intratumor and Intertumor Heterogeneity in Melanoma
Tomasz M. Grzywa et al.
TRANSLATIONAL ONCOLOGY (2017)
QuPath: Open source software for digital pathology image analysis
Peter Bankhead et al.
SCIENTIFIC REPORTS (2017)
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
Jeffrey E. Gershenwald et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Immunohistochemical analysis of T-type calcium channels in acquired melanocytic naevi and melanoma
O. Maiques et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Diagnosis and treatment of in-transit melanoma metastases
A. Testori et al.
EJSO (2017)
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
Nicholas McGranahan et al.
CELL (2017)
Identification of a Novel Pathogenic Germline KDR Variant in Melanoma
Ines P. Silva et al.
CLINICAL CANCER RESEARCH (2016)
Next-generation sequencing: advances and applications in cancer diagnosis
Simona Serrati et al.
OncoTargets and Therapy (2016)
Genomic Classification of Cutaneous Melanoma
Rehan Akbani et al.
CELL (2015)
Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma
Michael T. Tetzlaff et al.
HUMAN PATHOLOGY (2015)
Beyond BRAFV600: Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma
Alan E. Siroy et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis
Yu Sun et al.
JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION (2015)
Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma
Soo Young Kim et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma
Imke Satzger et al.
ONCOTARGET (2015)
BRAF and NRAS Mutations are Heterogeneous and Not Mutually Exclusive in Nodular Melanoma
Caterina Chiappetta et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2015)
BRAFV600E Protein Expression in Primary Cutaneous Malignant Melanomas and Paired Metastases
Hanna Eriksson et al.
JAMA DERMATOLOGY (2015)
Intrapatient Homogeneity of BRAFV600E Expression in Melanoma
Alexander M. Menzies et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2014)
Association between BRAF V600E and NRAS Q61R mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma
Shaowei Wu et al.
CANCER CAUSES & CONTROL (2014)
BRAFV600E immunopositive Melanomas Show Low Frequency of Heterogeneity and Association With Epithelioid Tumor Cells A STROBE-Compliant article
Ivana Verlinden et al.
MEDICINE (2014)
BRAFV600 mutation levels predict response to vemurafenib in metastatic melanoma
Celeste Lebbe et al.
MELANOMA RESEARCH (2014)
Pathways and therapeutic targets in melanoma
Emma Shtivelman et al.
ONCOTARGET (2014)
Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study
Nancy E. Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma
Alexander M. Menzies et al.
CLINICAL CANCER RESEARCH (2012)
Population-Based 20-Year Survival Among People Diagnosed With Thin Melanomas in Queensland, Australia
Adele C. Green et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma
Farhad Azimi et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
From genes to drugs: targeted strategies for melanoma
Keith T. Flaherty et al.
NATURE REVIEWS CANCER (2012)
Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis
J. -H. Lee et al.
BRITISH JOURNAL OF DERMATOLOGY (2011)
Identification of high-risk patients among those diagnosed with thin cutaneous melanomas
Phyllis A. Gimotty et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
NRAS and BRAF mutations in melanoma turnours in re ation to clinical characteristics:: a study based on mutation screening by pyrosequencing
Esther Edlundh-Rose et al.
MELANOMA RESEARCH (2006)
Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies
Gerald Saldanha et al.
CLINICAL CANCER RESEARCH (2006)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Share Paper
